Haleon plc key statistics and ratios
In fiscal 2025, Haleon plc had return on equity of 10.4%, an operating margin of 21.9%, debt equal to 52.4% of equity and a current ratio of 0.92. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|
| Gross margin | 59.7% | 62.3% | 60.6% | 59.7% | 60.7% | 64.2% |
| Operating margin | 16.2% | 17.2% | 16.8% | 17.7% | 19.6% | 21.9% |
| Net margin | 11.6% | 14.6% | 9.8% | 9.3% | 12.8% | 15.1% |
| Free-cash-flow margin | 12.0% | 11.8% | 16.2% | 16.5% | 18.3% | 21.0% |
| Return on equity | 4.1% | 5.4% | 4.7% | 6.4% | 8.9% | 10.4% |
| Return on assets | — | 4.1% | 3.0% | 3.1% | 4.3% | 5.1% |
| Asset turnover | — | 0.28 | 0.30 | 0.33 | 0.33 | 0.34 |
| Current ratio | — | 1.24 | 0.93 | 1.04 | 0.98 | 0.92 |
| Debt to equity | 0.0% | 0.6% | 63.9% | 56.9% | 62.6% | 52.4% |
| Effective tax rate | 25.8% | 12.0% | 30.8% | 31.8% | 22.8% | 21.9% |
| R&D as % of revenue | 3.1% | 2.7% | 2.8% | 2.8% | 2.7% | 2.9% |
| Capital spending as % of revenue | 2.2% | 2.4% | 2.8% | 2.1% | 2.2% | 2.9% |
| Free cash flow ÷ net income | 103.5% | 81.2% | 165.9% | 177.9% | 142.2% | 138.7% |
| Dividends and buybacks ÷ free cash flow | — | — | — | 2.0% | — | — |
Financial health
- Short-term assets cover short-term liabilities $6.1bn of assets due within a year against $6.6bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $6.1bn short-term assets against $15.1bn of longer-dated liabilities.
- More cash than debt $1.8bn of cash against $10.5bn of debt.
- Debt below 40% of shareholders' equity Debt is 47% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt $3.5bn of operating cash flow against $10.5bn of debt.
- Operating profit covers interest at least five times over Operating income of $3.2bn against $9m of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Viatris statistics
- Universe Pharmaceuticals Inc statistics
- Bausch Health Companies Inc. statistics
- Zoetis statistics
- Organon & Co. statistics
Head to head: HLN vs VTRSHLN vs UPCBHC vs HLNHLN vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies